Principle III: Value-Driven Program Execution
All studies (
in vitro
, non-clinical, clinical, and CMC) must be designed to produce knowledge that directly impacts expected product value, as specified in the Target Product Profile, and data to support the labeled claims.
Market Advantage
Product Readiness
Value-Driven Program Execution
Learning and Confirming
Regulatory Collaboration
News
|
About Us
|
Our Team
|
Development Principles
|
Contact Us
|
Home
© 2005-2008 NDA Partners
Site by:
New Village Media
